OMER News and Press, Omeros Corporation From 05/18/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Retailers cap off the Q1 earnings season in style as Target (TGT), Best Buy (BBY), ...

Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at 8:00 a.m. EDT. The presentatio...

Omeros Corporation (OMER) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Jennifer Williams – Investor Relations Greg Demopulos – Chairman and Chief Executive Officer Mike Jacobsen – Chief Accounting Officer Conference Call Par...

Q1 revenue of $21.8M was shy of estimates for closer to $23M. The company takes note of seasonally lower volume of cataract surgery performed in Q1, and the timing of normal wholesaler purchases shifting from the end of March to the first week in April. More news on: Omeros Corporation, He...

Omeros (NASDAQ: OMER ): Q1 GAAP EPS of -$0.50 misses by $0.08 . Revenue of $21.78M  misses by $1.4M . Press Release More news on: Omeros Corporation, Earnings news and commentary, Healthcare stocks news,

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targe...

- Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids- Omeros Corporation (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug OMIDRIA ® (phen...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. East...

Omeros Corporation (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA-approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be presented at the American Society of Cataract and Ref...

-- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- Omeros Corporation (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of gastrointestinal hematopoietic ...